Health and Fitness Health and Fitness
Tue, March 5, 2013
[ Tue, Mar 05th 2013 ] - Market Wire
30 a.m. ET
Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013
Tue, February 26, 2013
Mon, February 25, 2013
Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013

Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013


//health-fitness.news-articles.net/content/2013/ .. owen-health-care-conference-on-march-5-2013.html
Published in Health and Fitness on Friday, February 22nd 2013 at 7:16 GMT by Market Wire   Print publication without navigation


February 22, 2013 10:00 ET

Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013

PALATINE, IL--(Marketwire - Feb 22, 2013) -  Acura Pharmaceuticals, Inc. (NASDAQ: [ ACUR ]), a specialty pharmaceutical company developing products intended to address [ medication abuse and misuse ], announced today that the Company will present at the Cowen and Company Health Care Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013. Bob Jones, Acura Pharmaceutical's Chief Executive Officer, will provide a company update at 8:40AM Eastern Time. In advance of this presentation the Company plans to report financial results for the fourth quarter and fiscal year ended December 2012 following the close of markets on Monday, March 4, 2013.

 A live webcast of the presentation will be available through the "[ Investors ]" page of Acura's website: [ www.acurapharm.com ]. An archived version of the presentation will be available for 30 days after the event.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HC1 tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids. 

In December 2012, the Company commenced commercialization of Nexafed® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE™ technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

The trademark OXECTA® is owned by Pfizer Inc.



Publication Contributing Sources